Imcyse obtains authorization to launch Phase 1b trial in Type 1 diabetes
Imcyse’s first clinical trial involves its active, specific immunotherapy technology, a unique approach with the potential to cure and/or prevent severe chronic autoimmune diseases, including those for which there is currently no cure